Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor Maintenance in PTCL
NCT05822050Phase 3Unknown
- Sponsor
- The First Hospital of Jilin University
- Start
- Jun 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of selinexor in peripheral T-cell lymphoma (PTCL) (2 arms), sponsored by The First Hospital of Jilin University. Primary endpoint: Progression Free Survival rate of 1 year. Status: unknown.
02
Drugs
selinexor
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT05822050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05822050.